{
    "root": "35ce799a-fb7a-23e6-e063-6394a90af69d",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Letrozole",
    "value": "20250523",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "LETROZOLE",
            "code": "7LKK855W8I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6413"
        }
    ],
    "indications": {
        "text": "letrozole tablet aromatase inhibitor indicated : adjuvant treatment postmenopausal women hormone receptor positive early breast cancer ( 1.1 ) extended adjuvant treatment postmenopausal women early breast cancer received prior standard adjuvant tamoxifen therapy ( 1.2 ) first second-line treatment postmenopausal women hormone receptor positive unknown advanced breast cancer ( 1.3 )",
        "doid_entities": [
            {
                "text": "breast cancer (DOID:1612)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1612"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "letrozole tablets taken orally without regard meals ( 2 ) : recommended dose : 2.5.mg daily ( 2.1 ) patients cirrhosis severe hepatic impairment : 2.5 mg every day ( 2.5 , 5.3 )",
        "doid_entities": [
            {
                "text": "cirrhosis (DOID:5082)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5082"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe hepatic impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "packaged hdpe bottles unit dose blister package . 2.5 mg tablets \u2013 yellow round , biconvex , film coated tablets imprinted 'lt ' one side plain side . bottles 30 tablets child-resistant closure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ndc 16729-034-10 bottles 90 tablets child-resistant closure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ndc 16729-034-15 bottles 100 tablets child-resistant closure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ndc 16729-034-01 bottles 500 tablets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ndc 16729-034-16 bottles 1000 tablets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ndc 16729-034-17 unit dose blister package 100 ( 10x10 ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ndc 16729-034-43 store 25\u00b0c ( 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "pregnancy : letrozole cause fetal harm [ ( 8.1 ) ] . pregnancy : letrozole cause fetal harm [ ( 8.1 ) ] . known hypersensitivity active substance , excipients [ ( 6 ) ] . known hypersensitivity active substance , excipients [ ( 6 ) ] .",
    "indications_original": "Letrozole tablet is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer ( 1.1 ) Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy ( 1.2 ) First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer ( 1.3 )",
    "contraindications_original": "Letrozole tablets are taken orally without regard to meals ( 2 ): Recommended dose:\u00a02.5.mg once daily ( 2.1 ) Patients with cirrhosis or severe hepatic impairment: 2.5\u00a0mg every other day ( 2.5 , 5.3 )",
    "warningsAndPrecautions_original": "Packaged in HDPE bottles and unit dose blister package.\n                  2.5\u00a0mg tablets \u2013 yellow round, biconvex, film coated tablets imprinted with 'LT' on one side and plain on other side.\n                  \u00a0\u00a0\u00a0\u00a0\u00a0 Bottles of 30 tablets with a child-resistant closure ...................................................................................NDC 16729-034-10\n                  \u00a0\u00a0\u00a0\u00a0\u00a0 Bottles of 90 tablets with a child-resistant closure ...................................................................................NDC 16729-034-15\n                  \u00a0\u00a0\u00a0\u00a0\u00a0 Bottles of 100 tablets with a child-resistant closure..................................................................................NDC 16729-034-01\n                  \u00a0\u00a0\u00a0\u00a0\u00a0 Bottles of 500 tablets.................................................................................................................NDC 16729-034-16\n                  \u00a0\u00a0\u00a0\u00a0\u00a0 Bottles of 1000 tablets................................................................................................................NDC 16729-034-17\n                  \u00a0\u00a0\u00a0\u00a0\u00a0 Unit dose blister package 100 (10x10)...................................................................................................NDC 16729-034-43\n                  Store at 25\u00b0C (77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Pregnancy: Letrozole can cause fetal harm\n  \n   [see Use in Specific Populations (\n   \n    8.1)]\n  \n   . Pregnancy: Letrozole can cause fetal harm\n  \n   [see Use in Specific Populations (\n   \n    8.1)]\n  \n   .\n \n  \n                     Known hypersensitivity to the active substance, or to any of the excipients\n  \n   [see Adverse Reactions (\n   \n    6)]\n  \n   . Known hypersensitivity to the active substance, or to any of the excipients\n  \n   [see Adverse Reactions (\n   \n    6)]\n  \n   .",
    "drug": [
        {
            "name": "Letrozole",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6413"
        }
    ]
}